Participatiefonds Duurzaam Economie

The fund sources exclusively inside Noord-Holland, filtering companies through ROM InWest’s business-development unit before it invests. That team works with founders to strengthen their business case, making the company investable while simultaneously building the fund’s pipeline. Only once a company meets the dual financial-and-societal-return threshold does the fund commit capital.

Participatiefonds Duurzaam Economie invests directly in startups, scale-ups, and SMEs headquartered in Noord-Holland. Its portfolio page shows direct equity stakes in companies such as Thorizon, Healthplus.ai, LIFEPOWR, and Amplio Pharma. There is no public evidence of fund-of-fund commitments or reliance on external GP vehicles.

The firm’s strategy spans early-stage, start-up, and growth-stage companies, according to its own activity classification. Its mandate reaches from founding-stage ventures like HeartEye through later rounds such as the €1.3 million raise for Amplio Pharma. The business-development arm suggests heavy engagement at pre-seed and seed stages.

The fund is one of several vehicles operated by ROM InWest, the regional development organization for Noord-Holland. It sits alongside the Transitiefonds and MKB fonds under the same organizational umbrella, with the ROM providing the business-development support that feeds the investment pipeline.

The fund’s four transition pillars — circular economy, digital systems, energy transition, and sustainable food — effectively exclude sectors without a clear societal-impact link. It does not invest in companies outside Noord-Holland, and its dual-return requirement screens out pure financial plays with no measurable social or environmental benefit.

Public sources do not detail the fund’s capital base. The close integration with ROM InWest and the regional mandate suggest backing from provincial or national economic-development budgets, but exact limited-partner identities and fund sizes remain undisclosed.

No named principals, managing directors, or investment-committee members are publicly disclosed on the firm’s website or in the scraped materials. The team page contains no individual biographies, making it impossible to attribute decision-making authority to specific individuals from current sources.